Brazilian liver cancer study reveals Real-World treatment patterns
NCT ID NCT06230328
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study reviewed medical records of 300 liver cancer patients treated in Brazil between 2017 and 2022. Researchers aimed to understand patient characteristics, how the cancer was managed, and survival outcomes. No new treatments were tested; instead, the goal was to gather real-world evidence to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
300 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Nov 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants with a hepatocellular carcinoma diagnosis (early and intermediate), meeting the eligibility criteria, who have had a 1st time visit to the study sites between 2017 and 2022, and with at least 2 visits with accessible information in the medical record will be included.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and female; * Above 18 years old; * Hepatocellular carcinoma diagnosis (confirmed by biopsy or imaging); Exclusion Criteria: * Fibrollamelar carcinoma, hepatoblastoma, intrahepatic cholangiocarcinoma, neuroendocrine tumors or other less common types of liver tumors; * Patients with incomplete staging data; * Patients with only 1 visit to the participating site healthcare service, with loss to follow-up prior to the second visit to the participating site healthcare service; * Previous treatment for hepatocellular carcinoma in another institution; * Treatment with investigational drugs in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Barretos, Brazil
-
Research Site
Belo Horizonte, Brazil
-
Research Site
Curitiba, Brazil
-
Research Site
Natal, Brazil
-
Research Site
Porto Alegre, Brazil
-
Research Site
Recife, Brazil
-
Research Site
Rio de Janeiro, Brazil
-
Research Site
Salvador, Brazil
-
Research Site
São Bernardo do Campo, Brazil
-
Research Site
São Paulo, Brazil
-
Research Site
Vitória, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
- AI-Enhanced ultrasound aims to catch liver cancer earlier
- Can turbocharged immune cells stop liver cancer from coming back?
- Two blood markers put to the test for early liver cancer detection
- New antibody pair takes aim at advanced liver cancer in major trial
- New antibody aims to preserve immune checkpoint while fighting cancer